应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
REGN 再生元制药公司
休市中 05-22 16:00:00 EDT
638.88
-3.71
-0.58%
盘后
637.00
-1.88
-0.29%
19:55 EDT
最高
644.12
最低
632.72
成交量
99.50万
今开
639.24
昨收
642.59
日振幅
1.77%
总市值
675.42亿
流通市值
659.98亿
总股本
1.06亿
成交额
6.34亿
换手率
0.96%
流通股本
1.03亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜再生元制药盘中上涨3.25%，报648.97美元
行情直击 · 05-20
异动解读｜再生元制药盘中上涨3.25%，报648.97美元
再生元制药公司同意在并行私募中收购Parabilis Medicines约7500万美元普通股
美股速递 · 05-20
再生元制药公司同意在并行私募中收购Parabilis Medicines约7500万美元普通股
再生元制药公司：协议包含约22亿美元额外潜在里程碑付款及分级特许权使用费
美股速递 · 05-18
再生元制药公司：协议包含约22亿美元额外潜在里程碑付款及分级特许权使用费
再生元制药公司：根据协议条款，公司追加期权付款后可能推进更多靶点研究
美股速递 · 05-18
再生元制药公司：根据协议条款，公司追加期权付款后可能推进更多靶点研究
再生元制药公司：Leerink Partners下调评级至“与大盘持平”，目标价大幅削减至641美元
美股速递 · 05-18
再生元制药公司：Leerink Partners下调评级至“与大盘持平”，目标价大幅削减至641美元
市场聚焦：道明尼资源、新纪元能源、联合健康
投资观察 · 05-18
市场聚焦：道明尼资源、新纪元能源、联合健康
再生元制药(REGN)盘前大跌11% 核心药物Ⅲ期试验未达预期
金吾财讯 · 05-18
再生元制药(REGN)盘前大跌11% 核心药物Ⅲ期试验未达预期
再生元制药公司股价盘前重挫11.2%，因晚期黑色素瘤药物研究未达统计学显著性
美股速递 · 05-18
再生元制药公司股价盘前重挫11.2%，因晚期黑色素瘤药物研究未达统计学显著性
再生元制药关键试验未达主要终点：无进展生存期改善未具统计学显著性
美股速递 · 05-16
再生元制药关键试验未达主要终点：无进展生存期改善未具统计学显著性
再生元制药公布一线治疗不可切除或转移性黑色素瘤的Fianlimab（Lag-3抑制剂）联合疗法三期试验最新进展
美股速递 · 05-16
再生元制药公布一线治疗不可切除或转移性黑色素瘤的Fianlimab（Lag-3抑制剂）联合疗法三期试验最新进展
再生元制药REMODEL试验安全性结果与已知度普利尤单抗特征一致；不良事件发生率62%
美股速递 · 05-05
再生元制药REMODEL试验安全性结果与已知度普利尤单抗特征一致；不良事件发生率62%
再生元制药Dupixent治疗24周实现食管扩张性较基线改善9%
美股速递 · 05-05
再生元制药Dupixent治疗24周实现食管扩张性较基线改善9%
Dupixent®（度普利尤单抗）在嗜酸性粒细胞性食管炎（EoE）四期临床试验中展现食管功能改善效果
美股速递 · 05-05
Dupixent®（度普利尤单抗）在嗜酸性粒细胞性食管炎（EoE）四期临床试验中展现食管功能改善效果
再生元制药公司将下调医疗补助药品价格 未来美国药价拟与国际接轨
美股速递 · 04-24
再生元制药公司将下调医疗补助药品价格 未来美国药价拟与国际接轨
财报前瞻｜再生元制药公司本季度营收预计小幅增长，机构普遍维持看多
财报Agent · 04-22
财报前瞻｜再生元制药公司本季度营收预计小幅增长，机构普遍维持看多
再生元制药公布Cemdisiran治疗GMG的三期Nimble试验积极结果
美股速递 · 04-21
再生元制药公布Cemdisiran治疗GMG的三期Nimble试验积极结果
Cemdisiran每12周皮下注射一次，在全身型重症肌无力三期试验中展现快速、深度且持久的疾病控制效果
美股速递 · 04-21
Cemdisiran每12周皮下注射一次，在全身型重症肌无力三期试验中展现快速、深度且持久的疾病控制效果
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
21世纪经济报道 · 04-15
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
再生元制药公司向TELIX支付4000万美元首付款
美股速递 · 04-13
再生元制药公司向TELIX支付4000万美元首付款
Telix制药有限公司将获4000万美元预付款及高达21亿美元里程碑款项加特许权使用费
美股速递 · 04-13
Telix制药有限公司将获4000万美元预付款及高达21亿美元里程碑款项加特许权使用费
加载更多
公司概况
公司名称：
再生元制药公司
所属市场：
NASDAQ
上市日期：
--
主营业务：
再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。
发行价格：
--
{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":638.88,"timestamp":1779480000000,"preClose":642.59,"halted":0,"volume":995022,"hourTrading":{"tag":"盘后","latestPrice":637,"preClose":638.88,"latestTime":"19:55 EDT","volume":19360,"amount":12367785.6369,"timestamp":1779494157420,"change":-1.88,"changeRate":-0.002943,"amplitude":0.004508},"delay":0,"changeRate":-0.005773510325401946,"floatShares":103302739,"shares":105719806,"eps":41.06084,"marketStatus":"休市中","change":-3.71,"latestTime":"05-22 16:00:00 EDT","open":639.24,"high":644.12,"low":632.72,"amount":633885979.0094999,"amplitude":0.017741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.06084,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":642.59,"dividendRate":0.005618,"preHourTrading":{"tag":"盘前","latestPrice":632.4,"preClose":642.59,"latestTime":"09:29 EDT","volume":782,"amount":497919.8102,"timestamp":1779456552522,"change":-10.19,"changeRate":-0.015858,"amplitude":0.05383},"postHourTrading":{"tag":"盘后","latestPrice":637,"preClose":638.88,"latestTime":"19:55 EDT","volume":19360,"amount":12367785.6369,"timestamp":1779494157420,"change":-1.88,"changeRate":-0.002943,"amplitude":0.004508},"volumeRatio":0.6620620594199293,"impliedVol":0.2006,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"1134477169","title":"异动解读｜再生元制药盘中上涨3.25%，报648.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134477169","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134477169?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:54","pubTimestamp":1779285285,"startTime":"0","endTime":"0","summary":"5月20日，再生元制药盘中上涨3.25%，报648.97美元/股，成交额5288.26万美元。再生元制药所在的生物科技行业中，个股中，安进跌0.05%，Immunovant, Inc.涨25.03%，Silexion Therapeutics Corp涨112.27%，Roivant Sciences Ltd.涨11.8%，ImmunityBio, Inc.涨6.19%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164541553","title":"再生元制药公司同意在并行私募中收购Parabilis Medicines约7500万美元普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1164541553","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164541553?lang=zh_cn&edition=full","pubTime":"2026-05-20 05:00","pubTimestamp":1779224413,"startTime":"0","endTime":"0","summary":"Parabilis Medicines宣布，再生元制药公司已同意通过一项并行私募交易，购买其价值约7500万美元的普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","REGN","LU1974910355.USD","LU0823434740.USD","LU2362540622.SGD","LU2023250504.SGD","LU2362541513.USD","LU0823434583.USD","LU2089984988.USD","LU2237438978.USD","BK4585","BK4139","LU1917777945.USD","LU2362541273.HKD","LU0114720955.EUR","BK4588","LU0889565916.HKD","LU0058720904.USD","LU0053666078.USD","LU0289739699.SGD","LU2106854487.HKD","LU0823416689.USD","LU0109394709.USD","LU0882574055.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142060213","title":"再生元制药公司：协议包含约22亿美元额外潜在里程碑付款及分级特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1142060213","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142060213?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:01","pubTimestamp":1779102112,"startTime":"0","endTime":"0","summary":"再生元制药公司披露，最新达成的协议条款中，除了已公布的核心内容外，还包含了价值约22亿美元的额外潜在里程碑付款。\n此外，协议还设定了分级结构的特许权使用费安排，该安排将根据未来产品的商业化表现或特定销售目标的达成情况而动态调整。\n这些财务条款的加入，显著提升了此次交易的整体潜在价值，并体现了合作方对相关研发项目商业化前景的共同信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0823434740.USD","LU0058720904.USD","LU2237438978.USD","LU0114720955.EUR","BK4139","LU2362541513.USD","LU0109394709.USD","REGN","LU0289739699.SGD","LU1917777945.USD","LU0889565916.HKD","LU0882574055.USD","LU2106854487.HKD","BK4585","LU2089984988.USD","LU0823434583.USD","LU0053666078.USD","LU2023250504.SGD","LU0823416689.USD","LU2362541273.HKD","LU0320765992.SGD","LU1974910355.USD","LU2362540622.SGD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167587402","title":"再生元制药公司：根据协议条款，公司追加期权付款后可能推进更多靶点研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1167587402","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167587402?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:01","pubTimestamp":1779102110,"startTime":"0","endTime":"0","summary":"根据协议条款，若公司支付额外的期权付款，再生元制药公司可能启动针对更多靶点的研发项目。这一安排为该公司未来拓展研发管线提供了灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","REGN","LU1974910355.USD","LU0823434740.USD","LU2362540622.SGD","LU2023250504.SGD","LU2362541513.USD","LU0823434583.USD","LU2089984988.USD","LU2237438978.USD","BK4585","BK4139","LU1917777945.USD","LU2362541273.HKD","LU0114720955.EUR","BK4588","LU0889565916.HKD","LU0058720904.USD","LU0053666078.USD","LU0289739699.SGD","LU2106854487.HKD","LU0823416689.USD","LU0109394709.USD","LU0882574055.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190474575","title":"再生元制药公司：Leerink Partners下调评级至“与大盘持平”，目标价大幅削减至641美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190474575","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190474575?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:05","pubTimestamp":1779098717,"startTime":"0","endTime":"0","summary":"再生元制药公司（Regeneron Pharmaceuticals, REGN）的评级遭遇下调。投资机构Leerink Partners将其对该公司的投资评级从“跑赢大盘”（Outperform）调降至“与大盘持平”（Market Perform）。与此同时，该机构大幅下调了再生元制药的目标股价，从原先的792美元削减至641美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0114720955.EUR","LU2237438978.USD","LU1974910355.USD","LU0289739699.SGD","LU2468319806.SGD","LU0823416689.USD","LU0320765992.SGD","LU2089984988.USD","LU0823434740.USD","LU2362540622.SGD","LU0109394709.USD","LU2106854487.HKD","REGN","BK4588","LU2023250504.SGD","LU0053666078.USD","LU0058720904.USD","BK4139","LU2362541273.HKD","LU2362541513.USD","LU1917777945.USD","BK4585","LU0823434583.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114706209","title":"市场聚焦：道明尼资源、新纪元能源、联合健康","url":"https://stock-news.laohu8.com/highlight/detail?id=1114706209","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114706209?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:14","pubTimestamp":1779095680,"startTime":"0","endTime":"0","summary":"消息传出后，道明尼资源股价在盘前交易中飙升12%，而新纪元能源股价则小幅走低。据悉，这笔交易最快可能于今日达成。联合健康 ：这家健康保险巨头的股价在盘前下跌了5%，此前伯克希尔哈撒韦 在周五晚间披露已清仓其在该公司的股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU2498475776.HKD","LU2279689827.SGD","IE00BJT1NW94.SGD","LU2357125470.USD","LU1914381329.SGD","LU0823434740.USD","LU0109394709.USD","LU0472753341.HKD","LU2468319806.SGD","BK4534","LU0795875169.SGD","LU1093756325.SGD","LU0316494557.USD","LU0345770308.USD","LU0079474960.USD","LU0496365809.HKD","BK4103","IE00BMG7P702.HKD","LU1506573853.SGD","BK4550","LU1280957306.USD","LU1064131342.USD","LU2168564495.EUR","LU0175139822.USD","LU0511384066.AUD","LU1674673428.USD","LU2360032135.SGD","BK4548","IE0034235303.USD","IE0002270589.USD","LU0354030511.USD","SG9999013999.USD","BRKD","LU0266013472.USD","SG9999002224.SGD","LU0823434583.USD","BK4532","RYAAY","LU0187121727.USD","LU2298064838.USD","IE00BFTCPJ56.SGD","BK4139","LU0320765646.SGD","LU1261432733.SGD","LU1929549753.HKD","IE00B29SXL02.USD","LU1069347547.HKD","LU1854103824.USD","IE00BKPKM429.USD","LU2125154935.USD","SG9999002232.USD","IE00BD4GTW91.USD","LU2298322129.HKD","IE00B7SZLL34.SGD","LU1983299246.USD","LU2168564222.USD","LU0130103400.USD","IE00BK4W5L77.USD","IE000M9KFDE8.USD","LU2294711713.HKD","LU1814569148.SGD","BK4533","LU0648001328.SGD","SG9999001176.USD","LU1093756168.USD","LU0128525929.USD","LU0823416689.USD","BK4008","LU1267930227.SGD","IE00BBT3K403.USD","LU1621767737.EUR","LU2048586759.USD","LU0342679015.USD","LU0708995401.HKD","LU0211327993.USD","LU0689472784.USD","LU2357305700.SGD","LU2552382215.SGD","LU1551013342.USD","IE0009355771.USD","IE0005OL40V9.USD","LU0726765562.USD","LU0545039389.USD","LU0310799852.SGD","IE00B19Z9P08.USD","LU1066051498.USD","BK4606","LU2361044865.SGD","REGN","IE00B775H168.HKD","LU0965509101.SGD","LU1548497426.USD","LU2244417387.USD","BK4581","IE00BD4GTV84.USD","LU0965509010.AUD","LU1670627923.USD","LU1119994496.HKD","LU1720051108.HKD","LU0820561818.USD","LU2238339852.HKD","LU0672654240.SGD","IE00BJJMRY28.SGD","LU0980610538.SGD","LU0170899867.USD","LU0052756011.USD","LU2089284900.SGD","BK4176","SGXZ57979304.SGD","LU0289739699.SGD","LU1988902786.USD","LU1267930730.SGD","LU1162221912.USD","IE00BN29S564.USD","LU2023251221.USD","LU0912757837.SGD","NEE","LU1934455194.USD","BK4500","LU2394011477.USD","LU0203347892.USD","LU1670628061.USD","SGXZ31699556.SGD","LU0417517546.SGD","LU1989771016.USD","LU2461242641.AUD","LU1732799900.SGD","LU2324357040.USD","SG9999001176.SGD","LU0289960550.SGD","LU1153585028.USD","IE00BK4W5M84.HKD","LU0211326839.USD","LU1720051017.SGD","LU0528227936.USD","HK0000914660.USD","IE00BMG7P819.SGD","LU2112291526.USD","HK0000914686.HKD","LU1621767810.EUR","SG9999014914.USD","LU0203345920.USD","LU2491050071.SGD","BK4208","IE00B2PGVK34.USD","IE00B775SV38.USD","IE00B19Z3581.USD","LU2361045086.USD","IE00B19Z8X17.USD","LU1003077747.HKD","LU1366333091.USD","LU0234570918.USD","LU1066051225.USD","IE00BMG7P694.USD","LU0048573561.USD","LU1201861249.SGD","IE00B7KXQ091.USD","LU1623119135.USD","LU0312595415.SGD","LU2491050154.USD","LU0971096721.USD","LU0943347566.SGD","UNHW","LU2236285917.USD","IE00BFMHRM44.USD","IE0002141913.USD","LU0557290698.USD","LU2089283258.USD","LU0354030438.USD","IE00BWXC8680.SGD","LU1621768115.EUR","BK4597","LU0210528500.USD","LU0109391861.USD","LU2347655073.USD","IE00BMG7P926.USD","IE00BJJMRX11.SGD","LU1201861165.SGD","IE00BZ18W456.USD","LU0742534661.SGD","LU1712237335.SGD","LU0310800379.SGD","D","IE00BFSS7M15.SGD","LU0251131958.USD","IE00B29SXK94.USD","LU0786609619.USD","LU0122379950.USD","LU0345770993.USD","LU0823414478.USD","LU1571399168.USD","LU0708994859.HKD","LU0289961442.SGD","IE00B19Z8W00.USD","SGXZ81514606.USD","LU2028103732.USD","LU2168563687.JPY","LU0787776722.HKD","LU0057025933.USD","LU2552382058.USD","LU2108987350.USD","BRK.B","LU0289739343.SGD","DAL","LU0256863811.USD","LU2133065610.SGD","LU1934455277.USD","LU2089984988.USD","LU0724618433.USD","LU1066051811.HKD","LU2211814178.USD","IE00B19Z9Z06.USD","IE00BJLML261.HKD","IE00BKDWB100.SGD","LU2242649171.HKD","LU0029864427.USD","LU0107464264.USD","LU1978683503.SGD","BK4081","IE00B894F039.SGD","LU0114720955.EUR","LU2106854487.HKD","LU0211328371.USD","IE00BMG7P587.USD","SG9999018865.SGD","LU1917777945.USD","SG9999014906.USD","LU1778281490.HKD","IE00BLSP4452.SGD","LU0128525689.USD","LU1057294990.SGD","IE00BZ9MQY76.HKD","LU0889565916.HKD","LU0130102774.USD","IE00BZ18W340.USD","LU1061106388.HKD","LU0058720904.USD","IE00BN8TJ469.HKD","LU0353189680.USD","LU0689626769.HKD","LU0456855351.SGD","LU2168564149.EUR","LU0302445910.USD","LU1037948541.HKD","LU1496350502.SGD","LU2087625088.SGD","LU0976567544.SGD","LU2023250504.SGD","LU0661504455.SGD","UNH","IE00B1XK9C88.USD","IE00B2B36J28.USD","BK4154","LU2506951792.HKD","LU2362540622.SGD","LU2347655156.SGD","BK4585","IE00B3CCJ633.GBP","IE00BMQBXF63.USD","SGXZ51526630.SGD","IE00BSNM7G36.USD","BRKU","LU2637428348.USD","LU0234572021.USD","LU1084165304.USD","LU1974910355.USD","LU0820562030.AUD","LU0432979614.USD","LU0795875086.SGD","LU1035773651.USD","UNHG","LU0158827948.USD","LU0149725797.USD","LU0251132253.USD","LU2275660780.HKD","LU2487616109.SGD","BRKC","LU2125154778.USD","LU0320765992.SGD","LU0683600562.USD","LU0353189763.USD","LU0124384867.USD","LU0251142724.SGD","LU0157215616.USD","LU2111349929.HKD","LU0320765059.SGD","LU1267930573.SGD","LU0949170772.SGD","LU1674673691.USD","LU1023059063.AUD","LU1854104046.USD","IE0004445239.USD","LU1934455863.HKD","LU0648000940.SGD","LU0965509283.SGD","LU0077335932.USD","LU1366192091.USD","LU0094547139.USD","IE00BKVL7J92.USD","IE00B3S45H60.SGD","LU0211326755.USD","IE00B4R5TH58.HKD","LU1883866441.USD","LU0861579265.USD","LU0553294199.USD","LU0640476718.USD","LU0154236417.USD","LU0158827781.USD","LU0198837287.USD","LU1621768206.USD","IE00BZ1G4Q59.USD","LU1323610961.USD","LU1074936037.SGD","IE00BJTD4V19.USD","LU0238689110.USD","LU1291159041.SGD","LU0823414551.USD","LU1791710582.SGD","LU2552382132.HKD","LU0069063385.USD","LU2168564065.EUR","LU2249611893.SGD","SGXZ99366536.SGD","IE00BFSS8Q28.SGD","BK4220","LU0820561909.HKD","BRKW","SG9999018857.SGD","LU0124676726.USD","LU2237438978.USD","IE00BFXG1179.USD","M","LU1267930490.SGD","IE00B19Z9505.USD","LU2462611646.USD","LU2500361329.USD","LU1791710400.SGD","LU2271345857.HKD","LU1066053197.SGD","LU2023250843.SGD","IE0004445015.USD","IE00BLSP4239.USD","LU1037948897.HKD","IE00B19Z3B42.SGD","IE00BD4GTT62.SGD","LU0053666078.USD","LU0048584097.USD","LU1939255532.USD","SG9999017495.SGD","LU2384288077.EUR","IE00B1BXHZ80.USD","LU1363072403.SGD","BK4566","LU2362541513.USD","LU2361044949.HKD","LU0011850046.USD","LU0006061336.USD","LU1551013425.SGD","LU2264538146.SGD","LU2211815571.USD","LU0310800965.SGD","LU1718418525.SGD","SG9999014898.SGD","IE00BGHQF417.EUR","LU0097036916.USD","IE00BJTD4N35.SGD","LU2362541273.HKD","LU0882574055.USD","SG9999014880.SGD","BK4588","LU0965508806.USD","IE00B4JS1V06.HKD","LU1732800096.USD","LU2491049909.HKD","LU0738911758.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636026825","title":"再生元制药(REGN)盘前大跌11% 核心药物Ⅲ期试验未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2636026825","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636026825?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:53","pubTimestamp":1779094391,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再生元制药（REGN）盘前股价大幅下挫，下跌11.2%，报 619.97 美元。消息面上，。5 月 15 日，再生元制药宣布，其核心药物 fianlimab 联合西米普利单抗的 Ⅲ 期试验未达到主要终点。数据显示，高剂量联合治疗组中位无进展生存期为 11.5 个月，优于对照组的 6.4 个月，但试验 P 值为 0.0627，未达到统计学显著性要求，意味着疗效优势或为偶然结果。此次试验失利直接影响市场对该公司肿瘤领域竞争力的信心。尽管再生元制药将希望寄托于另一项与百时美施贵宝已获批疗法头对头的试验，但此次失败带来的不确定性，仍对其股价造成显著冲击，短期市场信心受挫。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300532","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0058720904.USD","LU2089984988.USD","LU0823434740.USD","REGN","LU1974910355.USD","LU0109394709.USD","LU2362541273.HKD","LU2468319806.SGD","LU0882574055.USD","LU0114720955.EUR","LU2106854487.HKD","BK1191","LU0823434583.USD","LU1917777945.USD","LU2023250504.SGD","LU0053666078.USD","BK4588","01477","LU0889565916.HKD","LU2237438978.USD","LU0320765992.SGD","LU2362540622.SGD","BK1574","BK4139","BK4585","LU0289739699.SGD","LU2362541513.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154313869","title":"再生元制药公司股价盘前重挫11.2%，因晚期黑色素瘤药物研究未达统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1154313869","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154313869?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:31","pubTimestamp":1779093075,"startTime":"0","endTime":"0","summary":"再生元制药公司股价在盘前交易中遭遇重挫，跌幅达11.2%。这一急剧下跌源于该公司一项备受关注的晚期黑色素瘤药物研究未能达到预设的主要终点，即未能在统计学上显示出显著的有效性。\n该消息对市场信心造成显著打击，凸显了新药研发在关键临床阶段所面临的高风险与不确定性。投资者迅速对此负面数据做出反应，导致股价大幅下挫。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1974910355.USD","LU0289739699.SGD","LU2362540622.SGD","REGN","LU0320765992.SGD","LU0109394709.USD","LU2106854487.HKD","LU0823434583.USD","LU0053666078.USD","LU1917777945.USD","BK4139","LU0823434740.USD","LU0823416689.USD","LU2237438978.USD","BK4588","LU2362541513.USD","LU2089984988.USD","LU2023250504.SGD","LU0882574055.USD","LU0889565916.HKD","LU2468319806.SGD","LU0058720904.USD","LU2362541273.HKD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149676722","title":"再生元制药关键试验未达主要终点：无进展生存期改善未具统计学显著性","url":"https://stock-news.laohu8.com/highlight/detail?id=1149676722","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149676722?lang=zh_cn&edition=full","pubTime":"2026-05-16 08:23","pubTimestamp":1778890989,"startTime":"0","endTime":"0","summary":"再生元制药公司一项临床试验的主要终点——无进展生存期的改善——未能达到统计学显著性标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1974910355.USD","LU0289739699.SGD","LU2362540622.SGD","REGN","LU0320765992.SGD","LU0109394709.USD","LU2106854487.HKD","LU0823434583.USD","LU0053666078.USD","LU1917777945.USD","BK4139","LU0823434740.USD","LU0823416689.USD","LU2237438978.USD","BK4588","LU2362541513.USD","LU2089984988.USD","LU2023250504.SGD","LU0882574055.USD","LU0889565916.HKD","LU2468319806.SGD","LU0058720904.USD","LU2362541273.HKD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122731183","title":"再生元制药公布一线治疗不可切除或转移性黑色素瘤的Fianlimab（Lag-3抑制剂）联合疗法三期试验最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1122731183","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122731183?lang=zh_cn&edition=full","pubTime":"2026-05-16 08:20","pubTimestamp":1778890817,"startTime":"0","endTime":"0","summary":"再生元制药公司（Regeneron Pharmaceuticals）就其研发的Fianlimab（一种Lag-3抑制剂）联合疗法，在一线治疗不可切除或转移性黑色素瘤患者中的三期临床试验提供了最新动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0109394709.USD","LU0823434583.USD","LU2362541513.USD","LU0114720955.EUR","LU1974910355.USD","LU0320765992.SGD","BK4139","LU2468319806.SGD","LU0058720904.USD","LU0823416689.USD","LU2362541273.HKD","BK4588","LU0289739699.SGD","LU2106854487.HKD","REGN","LU2023250504.SGD","LU0823434740.USD","LU0053666078.USD","LU2362540622.SGD","LU0882574055.USD","LU2237438978.USD","LU1917777945.USD","LU2089984988.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149675812","title":"再生元制药REMODEL试验安全性结果与已知度普利尤单抗特征一致；不良事件发生率62%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149675812","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149675812?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:10","pubTimestamp":1777979450,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其REMODEL临床试验的安全性数据与度普利尤单抗已知的安全性特征相符。试验结果显示，接受度普利尤单抗治疗的患者中不良事件发生率为62%。\n这一数据进一步验证了该药物在临床使用中的安全性表现，为后续临床应用提供了重要参考依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0109394709.USD","LU0823434583.USD","LU2362541513.USD","LU0114720955.EUR","LU1974910355.USD","LU0320765992.SGD","BK4139","LU2468319806.SGD","LU0058720904.USD","LU0823416689.USD","LU2362541273.HKD","BK4588","LU0289739699.SGD","LU2106854487.HKD","REGN","LU2023250504.SGD","LU0823434740.USD","LU0053666078.USD","LU2362540622.SGD","LU0882574055.USD","LU2237438978.USD","LU1917777945.USD","LU2089984988.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166184363","title":"再生元制药Dupixent治疗24周实现食管扩张性较基线改善9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166184363","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166184363?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:07","pubTimestamp":1777979234,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其与赛诺菲联合开发的Dupixent在临床试验中取得突破性进展。数据显示，治疗24周后，患者食管扩张性指标较基线水平显著提升9%。\n该结果来自针对嗜酸性粒细胞性食管炎患者的III期研究。食管扩张性改善意味着患者吞咽功能得到实质性恢复，这对长期受进食困难困扰的患者具有重要临床意义。\nDupixent作为全人源单克隆抗体，通过抑制IL-4和IL-13信号通路发挥治疗作用。此次研究还观察到患者组织学异常和症状评分均获得显著改善。\n这项突破为嗜酸性粒细胞性食管炎患者提供了新的治疗选择。目前该适应症尚未获得监管批准，相关数据将作为申报材料提交给药品监管机构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU2362541513.USD","LU0114720955.EUR","BK4588","LU0823434583.USD","LU0882574055.USD","LU2106854487.HKD","BK4139","LU0058720904.USD","LU0053666078.USD","REGN","LU2089984988.USD","BK4585","LU1917777945.USD","LU0109394709.USD","LU1974910355.USD","LU2023250504.SGD","LU2362541273.HKD","LU0889565916.HKD","LU0823416689.USD","LU2468319806.SGD","LU0289739699.SGD","LU2237438978.USD","LU0823434740.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170194083","title":"Dupixent®（度普利尤单抗）在嗜酸性粒细胞性食管炎（EoE）四期临床试验中展现食管功能改善效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1170194083","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170194083?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:02","pubTimestamp":1777978922,"startTime":"0","endTime":"0","summary":"再生元制药公司旗下药物Dupixent在针对嗜酸性粒细胞性食管炎的四期临床试验中取得积极进展。最新数据显示，该药物能显著改善患者的食管功能指标，为这一难治性疾病的治疗提供了新的临床证据。这一发现进一步验证了度普利尤单抗通过抑制IL-4和IL-13信号通路对EoE病理机制的干预作用。作为全球首个获批用于EoE的生物制剂，Dupixent此次四期试验数据将为其在真实世界的临床应用提供更充分的循证支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0058720904.USD","LU2362541273.HKD","LU0114720955.EUR","LU0289739699.SGD","LU0823416689.USD","LU2468319806.SGD","BK4585","REGN","LU2023250504.SGD","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","BK4588","LU2362541513.USD","LU2089984988.USD","LU2106854487.HKD","BK4139","LU2237438978.USD","LU0053666078.USD","LU2362540622.SGD","LU1974910355.USD","LU1917777945.USD","LU0823434583.USD","LU0823434740.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157184372","title":"再生元制药公司将下调医疗补助药品价格 未来美国药价拟与国际接轨","url":"https://stock-news.laohu8.com/highlight/detail?id=1157184372","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157184372?lang=zh_cn&edition=full","pubTime":"2026-04-24 03:49","pubTimestamp":1776973774,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，将下调其药品在医疗补助计划中的定价，并计划未来使美国市场的药品价格与其他国家保持一致。\n这一战略调整标志着该生物技术巨头在定价政策上的重大转变。公司表示，通过降低医疗补助价格，将提升药品可及性；而与国际价格接轨的长期目标，则旨在应对美国国内关于药价过高的持续批评。\n分析人士指出，此举可能对生物制药行业产生深远影响，或促使其他企业重新评估其定价模式。再生元的核心产品包括治疗眼疾的Eylea和湿疹药物Dupixent，这些重磅药物在美国市场的定价一直备受关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0823434583.USD","LU2237438978.USD","LU0114720955.EUR","BK4139","LU2468319806.SGD","LU0320765992.SGD","LU2023250504.SGD","LU0058720904.USD","LU2362540622.SGD","LU2362541513.USD","BK4588","LU0289739699.SGD","LU2362541273.HKD","LU0823434740.USD","LU1917777945.USD","LU1974910355.USD","REGN","BK4585","LU0053666078.USD","LU2089984988.USD","LU0109394709.USD","LU2106854487.HKD","LU0882574055.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111940710","title":"财报前瞻｜再生元制药公司本季度营收预计小幅增长，机构普遍维持看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1111940710","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111940710?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:06","pubTimestamp":1776820018,"startTime":"0","endTime":"0","summary":"再生元制药公司将于2026年04月29日发布业绩，市场关注核心产品与合作收入节奏对利润率的影响。上季度公司实现营收38.84亿美元，同比增长2.51%，毛利率43.09%，归属于母公司股东的净利润为8.45亿美元，净利率21.74%，调整后每股收益11.44美元，同比下降5.22%。综合这些因素，机构普遍维持对再生元制药公司中期增长的正向判断，短期利润率的波动被视为可接受的阶段性现象。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜再生元制药公司本季度营收预计小幅增长，机构普遍维持看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118749575","title":"再生元制药公布Cemdisiran治疗GMG的三期Nimble试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1118749575","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118749575?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:32","pubTimestamp":1776781935,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发药物Cemdisiran在针对全身性重症肌无力（GMG）的三期Nimble临床试验中取得积极成果。该试验达到主要终点和关键次要终点，显示药物能显著改善患者临床症状。Cemdisiran作为一款创新疗法，此次数据为其后续监管申请奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434740.USD","BK4588","LU2362541513.USD","LU2362540622.SGD","LU2023250504.SGD","LU0289739699.SGD","LU1974910355.USD","BK4585","BK4139","LU0053666078.USD","LU0109394709.USD","LU2106854487.HKD","LU2237438978.USD","REGN","LU0823434583.USD","LU2089984988.USD","LU1917777945.USD","LU0320765992.SGD","LU2468319806.SGD","LU0114720955.EUR","LU0882574055.USD","LU0889565916.HKD","LU0058720904.USD","LU2362541273.HKD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179614202","title":"Cemdisiran每12周皮下注射一次，在全身型重症肌无力三期试验中展现快速、深度且持久的疾病控制效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1179614202","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179614202?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:30","pubTimestamp":1776781822,"startTime":"0","endTime":"0","summary":"再生元制药公司研发的Cemdisiran在最新三期临床试验中取得突破性进展。该药物采用每12周一次皮下注射的给药方案，针对全身型重症肌无力患者展现出卓越的治疗效果。\n临床数据显示，Cemdisiran能够实现快速起效、深度缓解并维持长期疾病控制。这种创新疗法为患者提供了更为便捷的治疗选择，显著改善了用药依从性。\n试验结果证实，Cemdisiran在关键疗效指标上均表现出显著优势，为全身型重症肌无力的治疗开辟了新途径。该药物的长效特性有望重塑现有治疗格局，为患者带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU2362540622.SGD","LU2237438978.USD","LU0889565916.HKD","LU0823416689.USD","LU0058720904.USD","LU2362541513.USD","LU2023250504.SGD","BK4585","BK4588","LU1974910355.USD","LU2362541273.HKD","LU0882574055.USD","LU0053666078.USD","LU2468319806.SGD","LU2106854487.HKD","LU0114720955.EUR","LU0289739699.SGD","LU1917777945.USD","LU0823434740.USD","LU0320765992.SGD","LU0109394709.USD","BK4139","LU0823434583.USD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1093756325.SGD","300558","IE00BZ1G4Q59.USD","600513","NVO","600196","IE00BKVL7J92.USD","BK4599","BK4585","002437","301087","LU0154236417.USD","NVOH","BK4588","603087","688177","LU1093756168.USD","NVOX","REGN","02196","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182410565","title":"再生元制药公司向TELIX支付4000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1182410565","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182410565?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:33","pubTimestamp":1776076393,"startTime":"0","endTime":"0","summary":"根据最新合作协议，TELIX PHARMACEUTICALS LTD将获得来自再生元制药公司的一笔总额为4000万美元的预付款项。此次交易标志着两家生物技术企业在创新药物研发领域的重要合作进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU0823434740.USD","LU0882574055.USD","LU0823434583.USD","LU2362541513.USD","TLX.AU","LU0889565916.HKD","LU2106854487.HKD","LU2362540622.SGD","LU0109394709.USD","BK4139","LU0114720955.EUR","LU1917777945.USD","LU0053666078.USD","BK7067","LU0289739699.SGD","LU0320765992.SGD","LU1974910355.USD","BK4585","LU0058720904.USD","LU2089984988.USD","LU2237438978.USD","REGN","BK4588","LU0823416689.USD","LU2468319806.SGD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173287378","title":"Telix制药有限公司将获4000万美元预付款及高达21亿美元里程碑款项加特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1173287378","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173287378?lang=zh_cn&edition=full","pubTime":"2026-04-13 06:29","pubTimestamp":1776032954,"startTime":"0","endTime":"0","summary":"Telix制药有限公司（ASX: TLX）宣布达成一项重大许可协议，根据协议条款，公司将获得4000万美元的预付款。此外，若未来达成特定的研发、监管和商业化里程碑，Telix还有资格获得总额高达21亿美元的款项。协议还包括基于未来产品销售的特许权使用费安排。此项交易凸显了Telix在放射性药物领域领先技术的价值及其产品的巨大市场潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0823434583.USD","LU2237438978.USD","LU0114720955.EUR","BK4139","LU2468319806.SGD","LU0320765992.SGD","LU2023250504.SGD","LU0058720904.USD","LU2362540622.SGD","LU2362541513.USD","BK4588","LU0289739699.SGD","LU2362541273.HKD","LU0823434740.USD","LU1917777945.USD","LU1974910355.USD","BK7067","REGN","BK4585","LU0053666078.USD","LU2089984988.USD","TLX.AU","LU0109394709.USD","LU2106854487.HKD","LU0882574055.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.085},{"period":"1month","weight":-0.1443},{"period":"3month","weight":-0.1806},{"period":"6month","weight":-0.1548},{"period":"1year","weight":0.0704},{"period":"ytd","weight":-0.1723}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州注册成立。该公司是一家完全整合的生物技术公司，为患有严重疾病的人发明、开发、制造和商业化药物。其核心业务战略建立在科研和专有技术的强大基础之上，推进跨多个治疗领域的多样化产品和候选产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.086855},{"month":3,"riseRate":0.457143,"avgChangeRate":-0.043382},{"month":4,"riseRate":0.457143,"avgChangeRate":0.014275},{"month":5,"riseRate":0.611111,"avgChangeRate":0.053204},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}